GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI) - Evolution Group Plc

21 Dec 2011 11:51

RNS Number : 4172U
Credit Suisse Securities (Eur) Ltd
21 December 2011
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Credit Suisse Securities (Europe) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Evolution Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Evolution Group Plc

(d) Date position held/dealing undertaken:

20-December-2011

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

193

0.0001

15,796

-0.0324

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

TOTAL:

193

0.0001

15,796

-0.0324

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Ordinary shares

B

390727

76.00

Ordinary shares

S

324935

76.00

Ordinary shares

B

386095

75.98

Ordinary shares

S

386095

75.98

Ordinary shares

S

21051

75.97

Ordinary shares

B

457686

75.96

Ordinary shares

S

457686

75.96

Ordinary shares

S

7000

75.95

Ordinary shares

B

19532

75.92

Ordinary shares

S

19532

75.92

Ordinary shares

S

47700

75.90

Ordinary shares

B

26231

75.89

Ordinary shares

S

26231

75.89

Ordinary shares

S

13000

75.86

Ordinary shares

S

20000

75.82

Ordinary shares

S

7000

75.77

Ordinary shares

B

65554

75.75

Ordinary shares

S

17000

75.73

Ordinary shares

B

1405

75.50

 

Purchases 1,347,230

Sales 1,347,230

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21-December-2011

Contact name:

Liane Agostini / Anthony Allen / Paul MacDonald

Telephone number:

0207 888 3599 / 5416 / 8548

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEODKDDPDBDDKBB
Date   Source Headline
28th Mar 20197:00 amRNSPoster presentation of Imperial College data
25th Mar 20197:00 amRNSSFX-01 meets primary endpoints in STEM trial
18th Mar 20192:01 pmRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSUpdate on SFX-01 trial read-out dates
5th Mar 20197:00 amRNSSFX-01 data published in peer reviewed journal
6th Feb 20193:30 pmRNSHolding(s) in Company
5th Feb 20197:00 amRNSClinical trial update confirms read-outs on track
30th Jan 20195:28 pmRNSGrant of Options
23rd Jan 20197:00 amRNSSFX-01 featured in Nature Reviews Drug Discovery
22nd Jan 20197:00 amRNSChange of Adviser
19th Dec 20186:02 pmRNSShare option exercise and issue of equity
12th Dec 20187:00 amRNSInterim Results
10th Dec 20183:00 pmRNSNominated Adviser Status
4th Dec 20187:00 amRNSPoster Presentation of SFX-01 and Trial Update
3rd Dec 20187:00 amRNSNotification of Half Year Results
19th Nov 20187:00 amRNSInvestor Presentation in Manchester
8th Nov 20187:00 amRNSDirectorate Changes
23rd Oct 20189:57 amRNSHolding(s) in Company
18th Oct 20187:00 amRNSPlacing
18th Sep 20187:00 amRNSInvestor Symposium
11th Sep 20187:00 amRNSNotice of Investor Symposium
26th Jul 20183:22 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
25th Jul 20187:00 amRNSFinal Patient Recruited in STEM Phase IIa Trial
10th Jul 201811:00 amRNSGrant of share options, issue of equity and TVR
29th Jun 201810:45 amEQSHardman & Co Research: Evgen Pharma (EVG): 2018, a pivotal year
21st Jun 201812:30 pmRNSPosting of Annual Report and AGM Notice
13th Jun 20182:15 pmEQSHardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial
13th Jun 20187:00 amRNSFull Year Results
11th Jun 20189:05 amRNSSecond Price Monitoring Extn
11th Jun 20189:00 amRNSPrice Monitoring Extension
11th Jun 20187:00 amRNSInterim Update on STEM Trial
7th Jun 20184:40 pmRNSSecond Price Monitoring Extn
7th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20187:00 amRNSNotification of Preliminary Results
15th May 201811:00 amRNSPrice Monitoring Extension
14th May 20187:00 amRNSUpcoming Investor Presentations
2nd May 20187:00 amRNSGrant of further European patent
26th Apr 20184:40 pmRNSSecond Price Monitoring Extn
26th Apr 20184:35 pmRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSPresentation at World Orphan Drug Congress USA
20th Mar 20187:00 amRNSResearch Collaboration with Imperial College
5th Mar 20187:00 amRNSUpdate on Novel Sulforaphane Analogues
15th Jan 20187:00 amRNSPoster Presentation of SFX-01 Mechanistic Data
10th Jan 20184:31 pmRNSNotification of Major Interest in Shares
5th Jan 20189:49 amRNSNotification of Major Interest in Shares
5th Jan 20189:48 amRNSNotification of Major Interest in Shares
2nd Jan 20185:44 pmRNSTotal Voting Rights
28th Dec 201711:49 amRNSResult of General Meeting
22nd Dec 201710:10 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.